Investor Presentaiton

5-year financial targets for Therapy Selection & MRD INVESTOR 20 DAY 23 Revenue Growth >20% Combined Therapy Selection & MRD revenue CAGR (Total revenue excluding Screening) OpEx & CapEx $ Clinical ASPs by 2028 % Gross Margins . G360 > $3,000 Tissue > $2,000 • Response >$1,000 60-70% Combined Therapy Selection & MRD gross margin (Gross margin excluding screening) Reveal $1,000 $ Cash Flow • Leverage existing infrastructure • Therapy Selection cash flow breakeven end of 2023 GUARDANT™ • Combined Therapy Selection & MRD generates positive cash flow over cumulative 5-year period (Cash flow excluding Screening) 149

View entire presentation